Atara Biotherapeutics: Funding, Investors & Team (Sep 2026)

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Atara Biotherapeutics has raised $550k across 1 round on record. The most recent is an undisclosed round of $550k announced in May 2026.

Atara Biotherapeutics' most recent funding round on record is an undisclosed round of $550k, announced in May 2026.

FundedIQ lists Cokey Nguyen (Founder) at Atara Biotherapeutics.

Atara Biotherapeutics is based in South San Francisco, California, United States.

Atara Biotherapeutics is in the 101-250 employee band.

Atara Biotherapeutics' latest round of $550k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.